Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting267%
active_not_recruiting133%

Recent Activity

3 active trials
Showing 3 of 3
recruitingnot_applicable

ILR to Prevent BRCL_MCC 23608

NCT07127003
recruitingphase_3

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

NCT06144164
active_not_recruitingnot_applicable

Can ILR Reduce the Risk of Arm Lymphedema?

NCT05742945

Clinical Trials (3)

Showing 3 of 3 trials
NCT07127003Not Applicable

ILR to Prevent BRCL_MCC 23608

Recruiting
NCT06144164Phase 3

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

Recruiting
NCT05742945Not Applicable

Can ILR Reduce the Risk of Arm Lymphedema?

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3